In a randomized trial of patients with a previous myocardial infarction and with residual inflammation, a monoclonal antibody targeting the LOX-1 receptor, thought to contribute to atherosclerotic plaque progression and inflammation, reduced soluble LOX-1 and interleukin-6 levels but did not lead to a substantial reduction in coronary plaque volume.
- Michelle L. O’Donoghue
- David A. Morrow
- Marc S. Sabatine
